🏢
🌐 Entity
Biosimilar
Variant of a biopharmaceutical
📊 Rating
2 news mentions · 👍 0 likes · 👎 0 dislikes
📌 Topics
- Pharmaceutical Performance (2)
- Product Development (1)
- Financial Outlook (1)
- Biosimilar Growth (1)
- Financial Results (1)
- Market Challenges (1)
🏷️ Keywords
Biosimilars (2) · Gedeon Richter (1) · Pharmaceutical revenues (1) · Clean EBIT growth (1) · Women's healthcare (1) · Fiscal 2026 guidance (1) · Product launches (1) · R&D spending (1) · Sandoz (1) · Pharmaceuticals (1) · Earnings Results (1) · Revenue Growth (1) · Generic Drugs (1) · Financial Guidance (1) · Swiss Pharma (1)
📖 Key Information
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original "innovator" products and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.
📰 Related News (2)
🔗 Entity Intersection Graph
People and organizations frequently mentioned alongside Biosimilar:
-
Medication · 1 shared articles -
🏢
Sandoz · 1 shared articles
-
Gedeon Richter · 1 shared articles